- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 487/08 - Systèmes pontés
Détention brevets de la classe C07D 487/08
Brevets de cette classe: 1825
Historique des publications depuis 10 ans
|
103
|
110
|
114
|
121
|
135
|
131
|
185
|
182
|
171
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bristol-myers Squibb Company | 4886 |
95 |
| Janssen Pharmaceutica N.V. | 3625 |
37 |
| Boehringer Ingelheim International GmbH | 4762 |
35 |
| Merck Sharp & Dohme LLC | 3742 |
33 |
| Gilead Sciences, Inc. | 1949 |
31 |
| Novartis AG | 11297 |
28 |
| F. Hoffmann-La Roche AG | 7942 |
24 |
| Genentech, Inc. | 3864 |
24 |
| Vertex Pharmaceuticals Incorporated | 1570 |
22 |
| Pfizer Inc. | 3373 |
21 |
| Rigel Pharmaceuticals, Inc. | 586 |
20 |
| Hoffmann-La Roche Inc. | 3252 |
19 |
| Astellas Pharma Inc. | 1122 |
17 |
| Incyte Corporation | 961 |
16 |
| Biosplice Therapeutics, Inc. | 162 |
15 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2827 |
14 |
| Sanofi | 3863 |
14 |
| Astex Therapeutics Limited | 257 |
13 |
| Clarity Pharmaceuticals Limited | 44 |
13 |
| Amgen Inc. | 3894 |
12 |
| Autres propriétaires | 1322 |